Brinzolamide is a carbonic anhydrase inhibitor used for the reduction of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Although the exact pathophysiology of glaucoma is still unknown, one of the main hallmarks of this disease is vascular dysregulation and abnormalities.
- Mechanism
- Curator reviewed · 4 references
Brinzolamide is a highly specific, reversible, non-competitive inhibitor of carbonic anhydrases (CA), the enzymes catalyzing the reversible reaction of water and carbon dioxide (CO2) to form bicarbonate ions. Although there are 7 isoforms of CA in human tissues, brinzolamide has the highest affinity to CA II. Brinzolamide and its active metabolites were not found to displace any known ligands in vitro from their respective receptors or enzymes commonly involved in producing side effects or ancillary pharmacology, thus explaining brinzolamide's high order of safety.
- Primary indication
- Brinzolamide, either as a standalone agent or in combination with brimonidine, is approved by the FDA for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.Curator reviewed · 6 structured indications
- Formula / weight
- C12H21N3O5S3 · 383.507 g/mol (avg)
- First approval
- Canada, 2011 · United States, 1998 · European Union, 2016
- Code names
- AL-4862
- Brand names
Resolves to
HCRKCZRJWPKOAR-JTQLQIEISA-NSMILESCCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Brinzolamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account